Anaptysbio (ANAB) Files $500M Mixed Shelf
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
AnaptysBio (ANAB) PT Lowered to $52 at H.C. Wainwright
November 6, 2024 6:12 AM ESTH.C. Wainwright analyst Emily Bodnar lowered the price target on AnaptysBio (NASDAQ: ANAB) to $52.00 (from $55.00) while maintaining a Buy rating.
The analyst comments "3Q24 financial recap; lowering PT to $52 from $55. AnaptysBio had 3Q24 total operating expenses of $52.8M, which were slightly... More
AnaptysBio (ANAB) PT Lowered to $45 at Leerink Partners
November 6, 2024 5:58 AM ESTLeerink Partners analyst David Risinger lowered the price target on AnaptysBio (NASDAQ: ANAB) to $45.00 (from $47.00) while maintaining a Outperform rating.
The analyst comments " Bottom Line: ANAB reported 3Q results and stated that there have been no blinded safety issues to date with either its BTLA... More



